Lisanti Capital Growth’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.21M | Sell |
10,675
-41,900
| -80% | -$4.76M | 0.34% | 90 |
|
|
2025
Q1 | $5.53M | Buy |
52,575
+13,565
| +35% | +$1.43M | 1.64% | 13 |
|
|
2024
Q4 | $4.18M | Buy |
39,010
+14,225
| +57% | +$1.52M | 1.01% | 42 |
|
|
2024
Q3 | $2.48M | Buy |
+24,785
| New | +$2.48M | 0.63% | 70 |
|
|
2019
Q1 | – | Sell |
-17,601
| Closed | -$1.49M | – | 124 |
|
|
2018
Q4 | $1.49M | Sell |
17,601
-8,496
| -33% | -$719K | 0.6% | 67 |
|
|
2018
Q3 | $4.47M | Buy |
26,097
+3,166
| +14% | +$542K | 1.55% | 16 |
|
|
2018
Q2 | $2.96M | Buy |
22,931
+1,555
| +7% | +$201K | 1.13% | 34 |
|
|
2018
Q1 | $2.2M | Buy |
+21,376
| New | +$2.2M | 1.06% | 40 |
|
|
2016
Q3 | – | Sell |
-11,421
| Closed | -$850K | – | 102 |
|
|
2016
Q2 | $850K | Sell |
11,421
-2,237
| -16% | -$166K | 1.28% | 29 |
|
|
2016
Q1 | $912K | Buy |
13,658
+10,204
| +295% | +$681K | 1.08% | 40 |
|
|
2015
Q4 | $234K | Buy |
+3,454
| New | +$234K | 0.25% | 88 |
|
|
2014
Q2 | – | Sell |
-52,394
| Closed | -$2.2M | – | 105 |
|
|
2014
Q1 | $2.2M | Buy |
52,394
+19,893
| +61% | +$835K | 0.95% | 56 |
|
|
2013
Q4 | $1.07M | Buy |
+32,501
| New | +$1.07M | 0.45% | 82 |
|
|
2013
Q3 | – | Sell |
-40,388
| Closed | -$1.19M | – | 105 |
|
|
2013
Q2 | $1.19M | Buy |
+40,388
| New | +$1.19M | 0.57% | 69 |
|